Sahajanand Life Sciences Private Limited.
Sahajanand Life Sciences Private Limited. is a Private Non-govt company company incorporated in 2001 and based in Gujarat, India. Sahajanand Life Sciences Private Limited. operates in Chemical substances used in the manufacture of anti-biotic, manufacturing (NIC 24231) with authorized capital of ₹10.00 Cr and paid-up capital of ₹6.01 Cr. For 2023-24, the company reported revenue of ₹4.38 Cr and profit after tax of ₹50.85 L. The board has 2 active directors. RegisterKaro's provisional Compliance Health Score for the company is 100/100 (grade A), based on 4 of 9 signals — full scoring is pending extraction of the company's MCA filing history.
Quick facts
Directors
2 activeMCA Filings
Locked| Form | FY | Filed | Due | Delay | Status |
|---|---|---|---|---|---|
| AOC-4 | FY2024-25 | 30 Oct 2024 | 30 Oct 2024 | 0d | filed |
| MGT-7 | FY2024-25 | 25 Nov 2024 | 29 Nov 2024 | 0d | filed |
| AOC-4 | FY2023-24 | 30 Oct 2023 | 30 Oct 2023 | +14d | filed |
| MGT-7 | FY2023-24 | 26 Nov 2023 | 29 Nov 2023 | 0d | filed |
| AOC-4 | FY2022-23 | 30 Oct 2022 | 30 Oct 2022 | 0d | filed |
| MGT-7 | FY2022-23 | 25 Nov 2022 | 29 Nov 2022 | 0d | filed |
Full MCA filing history for Sahajanand Life Sciences Private Limited..
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Charges
Locked| Charge ID | Holder | Amount | Created | Status |
|---|---|---|---|---|
| 839756009 | ICICI Bank Ltd(Bank) | ₹4.19 Cr | 12 Mar 2021 | Open |
| 752299587 | Axis Bank Ltd(Bank) | ₹1.46 Cr | 12 Mar 2019 | Satisfied |
| 977728746 | Axis Bank Ltd(Bank) | ₹14.20 Cr | 27 Jan 2021 | Open |
| 953315562 | Kotak Mahindra Bank Ltd(Bank) | ₹13.22 Cr | 04 Jul 2019 | Open |
| 713353993 | Axis Bank Ltd(Bank) | ₹22.02 Cr | 12 Mar 2019 | Open |
| 930580456 | ICICI Bank Ltd(Bank) | ₹22.88 Cr | 27 Jan 2022 | Satisfied |
Charge IDs, lenders & amounts for Sahajanand Life Sciences Private Limited..
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Financial Performance
MCA| FY | Revenue | PAT | Net Worth | Total Assets | Employees |
|---|---|---|---|---|---|
| 2023-24 | — | ||||
| 2022-23 | — | ||||
| 2019-20 | — |
Detailed Financials
3 FYs| Line item | 2023-24 | 2022-23 | 2019-20 |
|---|---|---|---|
| Income statement | |||
| Revenue from operations | |||
| Other income | |||
| Total income | |||
| Total expenses | |||
| Profit before tax | |||
| Profit / (Loss) after tax | |||
| Balance sheet | |||
| Equity / Net worth | |||
| Borrowings | |||
| Current liabilities | |||
| Total liabilities | |||
| Current assets | |||
| Cash & equivalents | |||
| Total assets | |||
| Employees | — | — | — |
Cash-flow statement renders when the AOC-4 XBRL Cash Flow context is parsed during the extract phase.
Compounded Annual Growth Rate
| Metric | Latest value | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|
| Revenue2023-24 | -68.0% | — | — | |
| Profit after Tax2023-24 | -83.0% | — | — | |
| Net Worth2023-24 | +23.0% | — | — |
Financial Ratios
| FY | Revenue | PAT | PAT margin | Rev growth | ROE | ROA | D/E | Rev/emp |
|---|---|---|---|---|---|---|---|---|
| 2019-20 | +0.00% | — | — | +0.00% | — | |||
| 2022-23 | +28.64% | +78.80% | +99.34% | +16.77% | — | |||
| 2023-24 | +11.61% | -26.38% | +22.87% | +4.76% | — |
Cap Table & Shareholding
Locked| Category | Shareholders | Shares held | % |
|---|---|---|---|
| Promoters | 2 | 1,82,85,260 | 69.03% |
| Institutional Investors | 2 | 14,73,287 | 5.56% |
| Public & Others | 58 | 67,29,063 | 25.40% |
Promoter, institutional & public holding for Sahajanand Life Sciences Private Limited..
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Peer Benchmark
26 peersTop 10 in Chemical substances used in the manufacture of anti-biotic, manufacturing
by healthView all ›Events & timeline
3External data sources
7 plannedGSTIN Registrations
Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.
MSME Payment Delays
Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.
Related Party Transactions
Counterparty, nature, transaction value. Inter-company loans, sales, royalty.
Credit Ratings
Long-term + short-term ratings, with rationale on rating actions.
Trademarks
Applied, registered, opposed. Class numbers + status.
Patents
Applications and grants. Inventor names + filing dates.
Legal Cases
Ongoing + past litigations the entity is party to.
Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.